JP Morgan Chase’s Cardlytics CDLX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $872 | Buy |
+179
| New | +$1.34K | ﹤0.01% | 7346 |
|
|
2025
Q2 | – | Sell |
-2,023
| Closed | -$36.8K | – | 7129 |
|
|
2025
Q1 | $36.8K | Buy |
2,023
+155
| +8% | +$4.43K | ﹤0.01% | 5972 |
|
|
2024
Q4 | $69.3K | Buy |
1,868
+60
| +3% | +$2.3K | ﹤0.01% | 5893 |
|
|
2024
Q3 | $57.9K | Buy |
1,808
+23
| +1% | +$1.28K | ﹤0.01% | 5940 |
|
|
2024
Q2 | $147K | Sell |
1,785
-1,828
| -51% | -$198K | ﹤0.01% | 5324 |
|
|
2024
Q1 | $523K | Buy |
3,613
+1,183
| +49% | +$100K | ﹤0.01% | 4766 |
|
|
2023
Q4 | $224K | Buy |
2,430
+137
| +6% | +$13.9K | ﹤0.01% | 5333 |
|
|
2023
Q3 | $378K | Sell |
2,293
-412
| -15% | -$53.5K | ﹤0.01% | 4645 |
|
|
2023
Q2 | $171K | Sell |
2,705
-4,088
| -60% | -$248K | ﹤0.01% | 5170 |
|
|
2023
Q1 | $231K | Sell |
6,793
-1,527
| -18% | -$79.8K | ﹤0.01% | 4974 |
|
|
2022
Q4 | $480K | Buy |
8,320
+296
| +4% | +$18.3K | ﹤0.01% | 4549 |
|
|
2022
Q3 | $754K | Sell |
8,024
-7,220
| -47% | -$1.03M | ﹤0.01% | 4213 |
|
|
2022
Q2 | $3.4M | Sell |
15,244
-195,171
| -93% | -$65.4M | ﹤0.01% | 3115 |
|
|
2022
Q1 | $116M | Buy |
210,415
+4,422
| +2% | +$2.67M | 0.01% | 778 |
|
|
2021
Q4 | $136M | Buy |
205,993
+22,268
| +12% | +$17M | 0.02% | 737 |
|
|
2021
Q3 | $154M | Buy |
183,725
+6,286
| +4% | +$6.38M | 0.02% | 675 |
|
|
2021
Q2 | $225M | Sell |
177,439
-9,236
| -5% | -$10.4M | 0.03% | 566 |
|
|
2021
Q1 | $205M | Buy |
186,675
+41,546
| +29% | +$54.9M | 0.03% | 563 |
|
|
2020
Q4 | $207M | Buy |
145,129
+74,576
| +106% | +$79.5M | 0.03% | 516 |
|
|
2020
Q3 | $49.4M | Buy |
70,553
+9,784
| +16% | +$7.11M | 0.01% | 977 |
|
|
2020
Q2 | $42.5M | Buy |
60,769
+24,984
| +70% | +$14.4M | 0.01% | 967 |
|
|
2020
Q1 | $12.5M | Buy |
35,785
+32,590
| +1,020% | +$23.1M | ﹤0.01% | 1571 |
|
|
2019
Q4 | $2.01M | Sell |
3,195
-25,755
| -89% | -$12.6M | ﹤0.01% | 3381 |
|
|
2019
Q3 | $9.7M | Buy |
28,950
+9,020
| +45% | +$2.89M | ﹤0.01% | 2155 |
|
|
2019
Q2 | $4.9M | Buy |
19,930
+12,759
| +178% | +$2.55M | ﹤0.01% | 2677 |
|
|
2019
Q1 | $1.19M | Buy |
7,171
+2,965
| +70% | +$482K | ﹤0.01% | 3698 |
|
|
2018
Q4 | $455K | Buy |
4,206
+2,745
| +188% | +$463K | ﹤0.01% | 4179 |
|
|
2018
Q3 | $365K | Sell |
1,461
-3,854
| -73% | -$829K | ﹤0.01% | 4429 |
|
|
2018
Q2 | $1.16M | Buy |
5,315
+5,205
| +4,732% | +$963K | ﹤0.01% | 3747 |
|
|
2018
Q1 | $16K | Buy |
+110
| New | +$18.6K | ﹤0.01% | 5115 |
|
Other funds holding CDLX
6CM
WPM
JP Morgan Chase's CDLX Position: Q2 2026 in Review
JP Morgan Chase opened a new position in Cardlytics (CDLX) in Q2 2026: 179 shares worth $872. The stake represents ﹤0.01% of the portfolio and ranks #7346 among its holdings. This is a return to the name: JP Morgan Chase previously reported a position in CDLX as recently as Q1 2025.
JP Morgan Chase first reported a position in CDLX in Q1 2018 and has held it in 30 quarters since. The position peaked at $225M in Q2 2021. 43 funds tracked by Wall St. Rank hold CDLX as of Q2 2026.
- JP Morgan Chase held 179 shares of Cardlytics worth $872 as of Q2 2026.
- Cardlytics was a new JP Morgan Chase position in Q2 2026.
- Cardlytics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #7346 holding.
- JP Morgan Chase first reported a position in Cardlytics in Q1 2018 and has held it in 30 quarters since.
- JP Morgan Chase's Cardlytics position peaked at $225M in Q2 2021.
- 43 funds tracked by Wall St. Rank held Cardlytics as of Q2 2026.
Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.